Xi'an Glance Newtone Pharmaceutical

Xi'an Glance Newtone Pharmaceutical is a clinical-stage biopharmaceutical company based in China, primarily focused on the development of innovative treatments for chronic hepatitis B (CHB) and other liver diseases. The company's lead candidate, Pradefovir Mesylate, is a liver-targeting prodrug of adefovir designed to maximize therapeutic efficacy in the liver while minimizing systemic exposure and associated renal toxicity. Glance Newtone is currently advancing its pipeline through late-stage clinical trials in China, aiming to provide safer and more effective oral antiviral options for the large population of patients with chronic HBV infections. The company integrates drug discovery, clinical development, and regulatory expertise to address significant unmet medical needs in the field of hepatology.